Journal
CLINICA CHIMICA ACTA
Volume 483, Issue -, Pages 227-233Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2018.05.010
Keywords
Long non-coding RNA; CYTOR; Cancer; Prognosis; Meta-analysis
Categories
Funding
- Science and Technology Foundation of the Sichuan Province [2014JY0183, 2016FZ0099, 2017SZ0123]
- 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan Univrsity
Ask authors/readers for more resources
Background and aims: Increasing evidence has shown the critical role of long non-coding RNA cytoskeleton regulator (CYTOR) in cancers. The expression of CYTOR is reported to be up-regulated in many kinds of cancers, such as gastric cancer, hepatocellular carcinoma, colon cancer, lung adenocarcinoma, oesophageal squamous cell carcinoma and renal cell carcinoma. Here, we summarized related studies and performed a meta-analysis to investigate the prognostic value of CYTOR in multiple cancers. Methods: Eligible studies were retrieved from PubMed, Embase and Cochrane Library databases, and the role of CYTOR in cancers was evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs). The results were further validated using The Cancer Genome Atlas (TCGA) dataset. Results: Our results showed that elevated CYTOR expression was significantly associated with poor prognosis in cancer patients (overall survival, HR = 2.03, 95% CI = 1.73-2.38, P < 0.00001). In addition, increased CYTOR expression is associated with lymph node metastasis (OR = 2.76, 95% CI = 1.28-5.95, P = 0.01), advanced TNM stage (OR = 2.23, 95% CI = 1.48-3.38, P = 0.001) and higher tumour grade (OR = 1.54, 95% CI = 1.03-2.29, P = 0.04). Conclusion: Overall, this study indicates that CYTOR may serve as a prognostic biomarker for cancer patients during the follow-up.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available